Benutzer:Robertotto21/Claus-Michael Lehr
Claus-Michael Lehr (born in October 2, 1961 in Merzig) is a German professor for biopharmaceutics and pharmaceutical technology. His research focus lies on the development of in vitro cell culture models of biological barriers as well as modern drug delivery systems that are selective for these barriers or can overcome them.[1][2]
Background and personal life
[Bearbeiten | Quelltext bearbeiten]Prof. Lehr studied pharmacy from 1982 until 1984 at Johannes Gutenberg University in Mainz and from 1984 until 1987 at University of Hamburg. After receiving his license to practice as a pharmacist in 1987, he began his doctoral studies at the Center for Bio-Pharmaceutical Sciences (Leiden University, Netherlands) and received his doctorate in 1991. From 1991 until 1992, he worked as a postdoctoral fellow at University of Southern California (USC, Los Angeles) and from 1992 until 1993 at Leiden Academic Center for Drug Research (LACDR). In 1993, Lehr was appointed as a professor for pharmaceutical technology at Philipps University in Marburg. In 1995, he moved to Saarland University (Saarbrücken), where he became Professor at the Institute for Biopharmaceutics and Pharmaceutical Technology. Since 2009, Prof. Lehr has been head of the Department of Drug Derlivery and Biological Barriers at the newly founded Helmholtz Institute for Pharmaceutical Research Saarland (HIPS).[2]
Prof. Lehr speaks English, French and Dutch fluently. He is married and has three children. Besides, he is a passionate sailor and jazz percussionist.[3]
Work
[Bearbeiten | Quelltext bearbeiten]Prof. Claus-Michael Lehr is known for his research on and optimization of in vitro cell culture models of the (bacteria-infected and/or inflamed) lung and intestinal epithelium as well as the skin. However, his research also covers the eyes and bacterial membranes as well as biofilms and mucus.[1][4][5][6] His aim is to replace animal experiments, which are commonly used to address biopharmaceutical and pharmacological questions, but which are often insufficiently representative of the human organism. Another focus of his research is drug delivery systems to overcome the abovementioned barriers and to bring novel drug components, such as nucleic acids, specifically to their target. Prof. Lehr initiated the "Biological Barriers" conference, which has been taking place biannually since 1994.[7] Lehr is also co-founder of the Saarbrücken-based companies Across Barriers GmbH (1998) and PharmBioTec Research & Development GmbH.[2][8] He is also a co-founder of the Center for Bioinformatics (2000) of Saarland University. Since 2009, Prof. Lehr has been an Advisory Board Member of the Strathclyde Institute of Pharmacy and Biomedical Sciences (SIPBS) in Glasgow and Board Member of the International Society for Aerosols in Medicine (ISAM).[2]
Moreover, in 2009, Prof. Claus-Michael Lehr, Prof. Rolf Hartmann and Prof. Rolf Müller founded the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), a subsidiary of the Helmholtz Center for Infection Research.[2] This insitute was the first publicly funded research insitute dedicated to pharmaceutical sciences in Germany. Prof. Lehr is co-editor of the scientific journal European Journal of Pharmaceutics and Biopharmaceutics[9] and also co-founder of the Controlled Release Society (CRS) German Local Chapter e.V..
Besides, Claus-Michael Lehr was co-developer of the Pharmaceutical Aerosol Deposition Device on Cell Cultures (PADDOCC),[10] and the human Alveolar Epithelial Lentivirus immortalized cell line (hAELVi).[11]
Honors and awards
[Bearbeiten | Quelltext bearbeiten]- 2001, 2013, 2021 - Phoenix Award, Pharmaceutical Technology[2]
- 2009 - International Prize of the Belgian Society of Pharmaceutical Sciences[2]
- 2010 - Fellow of the American Society of Pharmaceutical Scientists, AAPS[2]
- 2010, 2011 - German Research Awards for Alternatives to Animal Testing[2]
- 2012 - Membre Correspondant Académie Nationale de Pharmacie (Paris, France)[12]
- since 2012 - Adjunct Faculty Member, University of Utah, USA[13]
- 2013 - Fellow of the International Controlled Release Society (CRS)[14]
- 2015, 2016, 2017, 2018 listed among the top 100 of the most influencial drug developers[15][16][17][18]
- 2016 - Guest Professorship of Galenus Foundation at MIT (USA), Lab Prof. Robert S. Langer[19]
- 2017 - CRS T. Nagai Research Award for Postdoctoral Mentorship of Prof. Maike Windbergs[20]
Memberships in advisory boards
[Bearbeiten | Quelltext bearbeiten]- 2019 - CIBER-BBN Member of the Scientific Advisory Board, Valencia, Spain[2]
- 2019 - Chairman Accreditation Committee, Pharmacy, University of Geneva and ETH, Switzerland[2]
- 2018 - Research Evaluation Panel, Department of Pharmacy, University of Copenhagen[2]
- 2016-19 - President of the Apotheker Jacob Foundation[2]
- since 2014 - Catalent Applied Drug Delivery Institute, USA[2]
- since 2013 - BioTechMed-Graz, Austria[2]
- since 2012 - LabEx LERMIT, Paris, France[2]
- since 1998 - Co-Editor Europe of European Journal of Pharmaceutics and Biopharmaceutics[2]
- since 1996 - Co-Founder of CRS Local Chapter Germany and various positions in the Board[2]
- ↑ a b Universität des Saarlandes: Prof. Dr. Claus-Michael Lehr. Abgerufen am 18. September 2021.
- ↑ a b c d e f g h i j k l m n o p q r 2021-CV-CML. HIPS, abgerufen am 18. September 2021.
- ↑ The Power List 2018 – Masters of the Bench - Claus-Michael Lehr. The Medicine Maker, 2018, abgerufen am 28. September 2021 (englisch).
- ↑ Henni-Karoliina Ropponen, Robert Richter, Anna K. H. Hirsch, Claus-Michael Lehr: Mastering the Gram-negative bacterial barrier - Chemical approaches to increase bacterial bioavailability of antibiotics. Band 172. Elsevier, Mai 2021, S. 339–360, doi:10.1016/j.addr.2021.02.014.
- ↑ Florian Graef, Sarah Gordon, Claus-Michael Lehr: Anti-infectives in Drug Delivery-Overcoming the Gram-Negative Bacterial Cell Envelope. In: Current Topics in Microbiology and Immunology. Band 398. Springer, Cham, März 2016, S. 475–496, doi:10.1007/82_2016_491.
- ↑ wirkstofftransport ueber biologische barrieren (HIPS Webpräsenz). Abgerufen am 18. September 2021.
- ↑ 13th International Conference and Workshop on Biological Barriers. Abgerufen am 18. September 2021.
- ↑ Pharmbiotec, Kontakt. Abgerufen am 18. September 2021.
- ↑ Editorial Board. Abgerufen am 18. September 2021.
- ↑ Stephanie Hein, Michael Bur, Ulrich F. Schaefer, Claus-Michael Lehr: A new Pharmaceutical Aerosol Deposition Device on Cell Cultures (PADDOCC) to evaluate pulmonary drug absorption for metered dose dry powder formulations. Hrsg.: European Journal of Pharmaceutics and Biopharmaceutics. Band 77, Nr. 1. Elsevier, Januar 2011, S. 132–138, doi:10.1016/j.ejpb.2010.10.003.
- ↑ Anna Kuehn, Stephanie Kletting, Cristiane de Souza Carvalho-Wodarz, Urska Repnik, Gareth Griffiths, Ulrike Fischer, Eckart Meese, Hanno Huwer, Dagmar Wirth, Tobias May, Nicole Schneider-Daum, Claus-Michael Lehr: Human alveolar epithelial cells expressing tight junctions to model the air-blood barrier. Hrsg.: ALTEX. Band 33, Nr. 3, März 2016, S. 251–260, doi:10.14573/altex.1511131.
- ↑ Académie Nationale de Pharmacie - Les membres. Abgerufen am 28. September 2021.
- ↑ Claus Michael Lehr - Home - Faculty Profile - The University of Utah. Abgerufen am 28. September 2021.
- ↑ Newsletter. Controlled Release Society, 2014, abgerufen am 29. September 2021.
- ↑ The Power List 2015. Abgerufen am 28. September 2021 (englisch).
- ↑ The Power List 2016. Abgerufen am 28. September 2021 (englisch).
- ↑ The Power List 2017. Abgerufen am 28. September 2021 (englisch).
- ↑ The Power List 2018. Abgerufen am 28. September 2021 (englisch).
- ↑ MIT 2016 - Galenus Privatstiftung. Abgerufen am 28. September 2021.
- ↑ The Nagai Foundation (Hrsg.): THE NAGAI FOUNDATION TOKYO AWARD RECIPIENTS （1986-2019）.